Every evidence-based option — from self-monitoring to prescription — and what the research supports for each.
Key Details: What You Can Do
A 1-minute view of what this section covers. Tap any item to read the full discussion.
Simply tracking menopausal symptoms for two weeks reduced physical symptoms by 42% in a controlled trial
In an RCT of 100 women, structured symptom self-monitoring significantly reduced physical symptoms and negative emotions versus control, with effects persisting after controlling for personality traits.
CBT-I achieved 54-84% insomnia remission in the largest menopause-specific trial — positioned as first-line across major guidelines
In a 3-arm RCT (n=150), CBT-I and sleep restriction therapy produced 40-43 minutes more nightly sleep than sleep hygiene education, delivered by nurse therapists for scalability.
low-dose estrogen patch with natural progesterone showed the most favorable thrombotic and stroke-risk profile in a review of over 2.6 million women
Route choice often turns on safety rather than efficacy — both transdermal and oral routes produced similar symptom improvement in a multicenter trial. See the Long-Term Health section for regimen-specific VTE nuances.
Evening primrose oil does not have sufficient evidence for hot flashes — a systematic review found no effect on frequency or duration
At 8 weeks, EPO performed worse than black cohosh for severity. The authors concluded: currently insufficient evidence to conclude EPO is beneficial for hot flashes.
Non-hormonal alternatives received satisfaction ratings of 2.0/5 vs 3.7/5 for hormone therapy among women unsuitable for HT
In a qualitative study of 32 HT-unsuitable women, 25% had never had their VMS treated. Evidence-based non-hormonal options exist for specific symptom domains but are generally less effective for vasomotor symptoms.
The treatment landscape for perimenopause is broader than most women realize — and the evidence behind each option varies dramatically. This section maps what is available, what the research supports, and where the evidence is thin or absent. It is organized by type of option, not by a suggested order.
Your decisions about treatment belong with you and your doctor, based on your specific symptoms, medical history, and preferences. Several of these options are explored in more detail in later sections: mood and sleep in the Mood, Sleep & Cognition section; hot flashes in the Vasomotor Symptoms section; genitourinary symptoms in the Genitourinary Health section; long-term cardiovascular, metabolic, and bone considerations in the Long-Term Health section; breast cancer context in the Breast Cancer & HRT section; and specific situations including premature ovarian insufficiency in the Special Populations section.
Behavioral and Self-Management Options
Symptom Self-Monitoring
Cognitive Behavioral Therapy for Insomnia (CBT-I)
Mind-Body Therapies
A systematic review and meta-analysis of 18 randomized controlled trials (1,572 women) found that mind-body therapies produced a large effect on sleep quality (SMD -0.86) — larger than their effect on depression (SMD -0.79) (102). Yoga and Qigong showed the most stable benefits for sleep; mindfulness and music therapy were more effective for emotional regulation.
Yoga specifically has been studied across 14 RCTs (1,057 women) and appears beneficial for overall menopausal symptoms compared to no treatment, with possible improvements in anxiety, depression, sleep, BMI, and blood pressure — though the evidence is low certainty with high heterogeneity (109).
Exercise
One important finding: in a Dutch cohort study of 9,942 women, menopausal symptom burden was strongly associated with high need for recovery after work (OR 4.51 per 10-point symptom increase), and lifestyle behaviors — including physical activity — did not moderate that association (94). Exercise independently benefits mood and recovery, but it does not buffer the workplace impact of menopausal symptoms. Workplace support should not depend on whether a woman exercises.
Supplements and Complementary Therapies
The evidence quality across complementary therapies is generally low. A systematic review of 158 studies (114 RCTs) found that 54% of included RCTs had high risk of bias, and 72% of the systematic reviews scored critically low on the AMSTAR2 quality tool. Only 6 of 114 RCTs were assessed as low risk of bias (109). That does not mean nothing works — but it means the strongest claims often rest on the weakest evidence.
Black cohosh (isopropanolic extract) has the strongest complementary therapy signal — moderate-certainty evidence from 22 RCTs (2,310 women) showing benefit for vasomotor symptoms and overall menopausal symptoms. It is generally safe (109).
Soy isoflavones show a small but statistically significant effect on overall menopausal symptoms (Hedges' g = -0.25, I²=0% — consistent across studies). Soy-derived isoflavones, not red clover-derived, showed benefit for hot flash frequency. The Genitourinary Health section covers a separate vaginal-dryness signal with high heterogeneity. Effects on breast tissue depend on endogenous estrogen concentrations, and women with estrogen-sensitive cancers or on anti-estrogen medication should discuss soy supplementation with their clinician (77).
Ashwagandha root extract showed a large effect on menopausal symptoms in one small trial (n=60, 56 days) using a specific branded product (KSM-66, supplied by Ixoreal Biomed Inc). The authors explicitly state that results may not be extrapolated to other ashwagandha preparations. The unusually large effect size and minimal placebo response warrant caution — this is a single-center, single-product, 8-week signal, not established evidence for ashwagandha as a category (111).
Evening primrose oil does not have sufficient evidence to support its use for hot flashes. A systematic review found no significant effect on hot flash frequency or duration. A short-term severity signal (<6 months) did not persist, and at 8 weeks EPO performed worse than black cohosh for severity (p=0.001). The authors concluded: "currently insufficient evidence to conclude that EPO is beneficial to alleviate hot flashes" (51).
Vitamin D and calcium have moderate-certainty evidence for reducing hip fractures in postmenopausal women over 65 with osteoporosis. In the general population, the WHI 13-year follow-up found no fracture difference. High-dose calcium (>1,000 mg/day) may raise blood pressure, and long-term calcium plus vitamin D supplementation may increase cardiovascular mortality after 7 years. Vitamin D itself has high-certainty safety evidence (109).
Manual acupuncture was not superior to sham for hot flash severity or frequency. Omega-3 showed no effect on hot flashes or sleep. High-dose vitamin E (≥400 IU/day) is associated with increased all-cause mortality (109).
Hormone Therapy
Hormone therapy remains the most effective treatment for in eligible women — this is consensus across IMS, FIGO, NAMS, and ICSM. But "hormone therapy" is not one thing. Formulation, route, dose, and the specific progestogen all affect both efficacy and risk.
Route and Formulation
However, the "transdermal is safer" shorthand needs qualification. A large Swedish study (919,614 women) found that transdermal estrogen used as part of combined estrogen-progestogen therapy still carried a VTE signal (HR 1.46-1.67), while transdermal unopposed estrogen did not. The Long-Term Health section breaks this down by specific regimen and endpoint.
In women with type 2 diabetes at low cardiovascular risk, showed advantages for glucose metabolism (33) — the opposite of the general route preference for cardiovascular safety. This is one of several areas where route selection depends on which comorbidity dominates a woman's individual risk profile.
When taken orally, less than 20% of circulates as progesterone itself. About 80% is converted into neurosteroid metabolites — allopregnanolone and pregnanolone — that act on GABA receptors in the brain (39). These metabolites are thought to explain why oral micronized progesterone can be sedating and may support sleep — effects that do not share, because they do not convert to these neurosteroids. Bedtime dosing is commonly used because drowsiness and dizziness can occur. Vaginal progesterone does not produce these neurosteroid effects at clinically significant levels. Note: the clinical sleep trial below tested oral micronized progesterone combined with transdermal estradiol — not oral MP alone.
[EVIDENCE] In the PERT trial (n=172, 12 months), transdermal estradiol 0.1 mg/day plus intermittent oral micronized progesterone improved sleep independently of its effects on hot flashes and depression (p=0.02 after controlling for both). This suggests a direct hormone-on-sleep pathway. (PMID 31688579, ref 6, PMID 31838497, ref 7)
For Mood Symptoms Specifically
Guideline discussions often favor an when mood symptoms are being treated hormonally and metabolic or thrombotic risk is relevant. CANMAT positions transdermal estrogens as second-line for perimenopausal depression (120). In a three-arm RCT (n=195, 12 weeks), the combination of plus significantly outperformed either treatment alone for both depression and anxiety scores (124). A parallel trial (n=166) showed the same combination pattern for insomnia (65).
For Genitourinary Symptoms
has the strongest evidence base for genitourinary syndrome of menopause, anchored to an AHRQ systematic review of 68 publications. Multiple formulations exist (estradiol tablets, softgel inserts, rings, creams; estriol gels and inserts; promestriene) — all show class-effect efficacy, and the choice is based on patient preference to support adherence. At recommended doses, local vaginal estrogen does not raise circulating estradiol above normal postmenopausal levels (86, 61).
reduces dyspareunia and vaginal dryness with minimal systemic sex-steroid increase. is now considered a first-line pharmacological alternative alongside local estrogen after 5-year VTE safety data (86). has not shown benefit over sham in controlled trials and is not recommended for routine clinical use.
The Genitourinary Health section covers these options in full detail.
For Premature Ovarian Insufficiency
In women with POI (ovarian activity lost before age 40) or early menopause (ages 40-45), hormone therapy functions as primary prevention for cardiovascular disease, type 2 diabetes, and osteoporosis — not merely symptom relief. Doses are higher than standard menopause treatment, and therapy continues until the usual age of natural menopause (~50). The Special Populations section covers POI-specific dosing, monitoring, and management.
Non-Hormonal Prescription Options
SSRIs and SNRIs
SSRIs and SNRIs are core treatments for major depressive disorder during menopause (FIGO consensus). Specific evidence-based options include , , and . is available separately from the depression dose. Venlafaxine also reduces hot flashes (120).
These medications carry their own tradeoffs: sexual dysfunction is common with SSRIs, SSRIs are associated with increased fracture risk, and SSRIs, pregabalin, and gabapentin all carry withdrawal and dependency concerns. Anticholinergic medications carry cognitive-decline risk. These side effects should be weighed honestly against the side effects of the symptoms themselves — and against the side effects of leaving symptoms untreated (88).
Neurokinin Receptor Antagonists
This is a new class of non-hormonal prescription medications that target the thermoregulatory pathways involved in hot flashes. was not significantly different from hormone therapy for VMS frequency reduction in an indirect network comparison (29). It carries an FDA black box warning for hepatotoxicity, requiring liver function testing before treatment and frequently during the first 9 months (64). showed no hepatotoxic signal but had higher rates of treatment-emergent adverse events and discontinuations. The Vasomotor Symptoms section covers the trial evidence for both in detail.
Testosterone
Testosterone is indicated for hypoactive sexual desire disorder (HSDD) in postmenopausal women — not for general well-being, cognition, depression, or musculoskeletal health. consistently improves sexual desire, arousal, orgasm frequency, and reduces sexual distress in women with HSDD (53). In the available trial and review data, common androgenic side effects such as localized hair growth and acne were generally mild and reversible.
Pilot data suggesting mood benefit (47% improvement, n=510) is hypothesis-generating only — a larger UK clinic dataset (n=920) found that adding testosterone to estradiol did not significantly improve mood beyond estradiol alone (p=0.47) (43, 66).
Contraception During Perimenopause
Perimenopause requires ongoing contraception — pregnancy remains possible during the transition. Women over 50 need contraception for 1 year after their final menstrual period; women under 50 need it for 2 years. No contraceptive method is contraindicated solely by age, and natural estrogen-containing formulations are preferred after 40 (84). The Making Your Decision section discusses how contraception fits into the broader treatment-planning conversation.
For Women Who Cannot Use Hormone Therapy
Questions to Bring to Your Doctor
"Given my specific symptoms and medical history, which treatment category makes the most sense to start with — and why?"
"If we're considering hormone therapy, what specific formulation, route, and dose are you recommending — and what is the evidence behind that choice?"
"What are the realistic side effects of this treatment, and how do they compare to the side effects of leaving my symptoms untreated?"
"Are there options I can try alongside or before prescription treatment — like CBT-I for sleep or structured exercise for mood?"
"I have [specific condition]. Does that change which options are available to me?"
